Type I Interferon Receptor Deficiency Prevents Murine Sjogren's Syndrome

被引:34
作者
Szczerba, B. M. [1 ]
Rybakowska, P. D. [1 ]
Dey, P. [1 ]
Payerhin, K. M. [1 ]
Peck, A. B. [2 ]
Bagavant, H. [1 ,3 ]
Deshmukh, U. S. [1 ,3 ]
机构
[1] Univ Florida, Div Nephrol, Ctr Immun Inflammat & Regenerat Med, Gainesville, FL 32610 USA
[2] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL USA
[3] Univ Virginia, Dept Pharmacol, HSC, Charlottesville, VA 22908 USA
基金
美国国家卫生研究院;
关键词
xerostomia; sialoadenitis; autoimmunity; salivary gland; mouse; interferons; SYNDROME-LIKE DISEASE; GENE-EXPRESSION; SALIVARY-GLANDS; IMMUNE-RESPONSES; INNATE IMMUNITY; MOUSE MODEL; MICE; ACTIVATION; PATHOGENESIS; UPDATE;
D O I
10.1177/0022034513483315
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
In Sjogren's Syndrome (SS), inherent glandular defects, autoimmunity, and mononuclear cell infiltration within the salivary glands cause reduced salivation leading to xerostomia. Excessive production of type I interferons (IFN), triggered by environmental and genetic factors, is considered pathogenic in this disorder. However, whether type I IFN production is causative or an outcome of the disease process is not known. To address this question, we introduced a deficiency of interferon alpha receptor 1 (Ifnar1) into B6.Aec1Aec2 mice, which are known to have the genetic loci necessary for developing a SS-like disorder. This new mouse strain, B6.Aec1Aec2Ifnar1(-/-), lacking type I IFN-mediated signaling, was characterized for pilocarpine-induced salivation, the presence of serum autoantibodies, sialoadenitis, and dacryoadenitis. Compared with the B6.Aec1Aec2Ifnar1(+/+) (wild-type) mice, the B6.Aec1Aec2Ifnar1(-/-)(knockout) mice had significantly lower mononuclear cell infiltration in the salivary and lacrimal glands. The knockout mice were completely protected from salivary gland dysfunction. Surprisingly, they had a robust autoantibody response comparable with that of the wild-type mice. These findings demonstrate that, in the absence of type I IFN-mediated signaling, systemic autoantibody responses can be dissociated from glandular pathology. Our study suggests that, in genetically susceptible individuals, the type I IFN pathway can instigate certain features of SS.
引用
收藏
页码:444 / 449
页数:6
相关论文
共 50 条
  • [1] Type I interferon signature in Sjogren's syndrome: pathophysiological and clinical implications
    Marketos, N.
    Cinoku, I.
    Rapti, A.
    Mavragani, C. P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (03) : S185 - S191
  • [2] Primary Sjogren's Syndrome and the Type I Interferon System
    Nordmark, Gunnel
    Eloranta, Maija-Leena
    Ronnblom, Lars
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2012, 13 (10) : 2054 - 2062
  • [3] Activation of the type I interferon pathway in primary Sjogren's syndrome
    Mavragani, Clio P.
    Crow, Mary K.
    JOURNAL OF AUTOIMMUNITY, 2010, 35 (03) : 225 - 231
  • [4] Type I Interferon Signaling Is Required for Dacryoadenitis in the Nonobese Diabetic Mouse Model of Sjogren Syndrome
    Chaly, Yury
    Barr, Jennifer Y.
    Sullivan, David A.
    Thomas, Helen E.
    Brodnicki, Thomas C.
    Lieberman, Scott M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (10)
  • [5] Sex Differences in a Murine Model of Sjogren's Syndrome
    Cihakova, Daniela
    Talor, Monica V.
    Barin, Jobert G.
    Baldeviano, G. Christian
    Fairweather, DeLisa
    Rose, Noel R.
    Burek, C. Lynne
    CONTEMPORARY CHALLENGES IN AUTOIMMUNITY, 2009, 1173 : 378 - 383
  • [6] Reduction of T Cell Receptor Diversity in NOD Mice Prevents Development of Type 1 Diabetes but Not Sjogren's Syndrome
    Kern, Joanna
    Drutel, Robert
    Leanhart, Silvia
    Bogacz, Marek
    Pacholczyk, Rafal
    PLOS ONE, 2014, 9 (11):
  • [7] Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis
    Nezos, Adrianos
    Gravani, Fotini
    Tassidou, Anna
    Kapsogeorgou, Efstathia K.
    Voulgarelis, Michael
    Koutsilieris, Michael
    Crow, Mary K.
    Mavragani, Clio P.
    JOURNAL OF AUTOIMMUNITY, 2015, 63 : 47 - 58
  • [8] Expression of type III interferons (IFNλs) and their receptor in Sjogren's syndrome
    Apostolou, E.
    Kapsogeorgou, E. K.
    Konsta, O. D.
    Giotakis, I.
    Saridaki, M. I.
    Andreakos, E.
    Tzioufas, A. G.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2016, 186 (03) : 304 - 312
  • [9] Type I IFN signature in primary Sjogren's syndrome patients
    Brkic, Zana
    Versnel, Marjan A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (04) : 457 - 467
  • [10] First association of Interleukin 12 Receptor Beta 1 Deficiency with sjogren's syndrome
    Sogkas, Georgios
    Atschekzei, Faranaz
    Schacht, Vivien
    von Falck, Christian
    Jablonka, Alexandra
    Jacobs, Roland
    Stoll, Matthias
    Witte, Torsten
    Schmidt, Reinhold E.
    FRONTIERS IN IMMUNOLOGY, 2017, 8